
FEBRUARY 2024

COVID-19 Outpatient Therapeutics

Clinical Decision Aid for Ages 12+ years

Adult or pediatric patients (ages 12 and older* weighing at least 40 kg) with mild to moderate COVID-19 and at high risk for progression to severe disease

* Age requirement does not apply for Veklury (remdesivir)



Consider one of the following therapeutics, if clinically appropriate and feasible¹:

Paxlovid (nirmatrelvir co-packaged with ritonavir)^{2,8} within 5 days of symptom onset if patient does not have severe renal impairment (eGFR <30mL/min) OR severe hepatic impairment (Child-Pugh Class C)

- **eGFR** \geq 60mL/min: 300 mg nirmatrelvir taken with 100 mg ritonavir twice daily for 5 days
- eGFR ≥ 30mL/min to < 60 mL/min: 150 mg nirmatrelvir taken together with 100 mg ritonavir twice daily for 5 days
- Evaluate concomitant use of CYP3A inducers and medications with high dependency on CYP3A for clearance as these may be contraindicated^{2,3,8}

OR

Veklury (remdesivir)⁴ 200 mg IV x 1 dose on Day 1, 100 mg IV x 1 on Days 2–3 begun within 7 days of symptom onset.

Prescribers must review and comply with the mandatory requirements outlined in **the Paxlovid** (nirmatrelvir co-packaged with ritonavir) EUA² or the Veklury Prescribing Information⁴.

If Paxlovid (nirmatrelvir co-packaged with ritonavir) and Veklury (remdesivir) are not available, feasible or

clinically appropriate, consider one the following alternative therapies.

Lagevrio (molnupiravir)⁵, if age 18 or over and not pregnant (if applicable). 800 mg by mouth every 12h for 5 days begun within 5 days of symptom onset.

- Lagevrio (molnupiravir)⁵ is not authorized for initiation of treatment in patients hospitalized due to COVID19.
- Lagevrio (molnupiravir) can be administered via nasogastric (NG) or orogastric (OG) Tube (12F or Larger), refer to instructions within the EUA Fact Sheet, Section 2.3.
- Prescribers must review and comply with the mandatory requirements outlined in the Lagevrio (molnupiravir) EUA⁶

COVID-19 convalescent plasma⁷ with high titers of anti-SARS-CoV-2 antibodies, can also be considered for the treatment of COVID-19 in certain patients with immunosuppressive disease or receiving immunosuppressive treatment.

References:


- 1 NIH COVID-19 Treatment Guidelines. Therapeutic Management of Nonhospitalized Adults With COVID-19. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/
- 2 Paxlovid EUA. https://www.fda.gov/media/155050/download
- 3 NIH's COVID-19 Treatment Guidelines Panel: Ritonavir-Boosted Nirmatrelvir (Paxlovid). https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir-paxlovid-/
- 4 Veklury (remdesivir) Prescribing Information. https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
- 5 Lagevrio EUA. https://www.fda.gov/media/155054/download
- 6 CDC Covid-19 Website. https://www.cdc.gov/coronavirus/2019-ncov/index.html
- 7 Fact Sheet for Health Care Providers: EUA of COVID-19 Convalescent Plasma for Treatment of COVID-19. https://www.fda.gov/media/141478/download
- 8 Paxlovid Prescribing Information. https://labeling.pfizer.com/ShowLabeling.aspx?id=19599





COVID-19 Outpatient Therapeutics

Clinical Decision Aid: Pediatric patients 28 days of age and older weighing 3 kg to less than 40 kg with mild to moderate COVID-19 and at high risk for progression to severe disease



Reference:

1 Veklury Prescribing Information: https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf

2 <u>NIH COVID-19 Treatment Guidelines Therapeutic Management of Nonhospitalized Adults With COVID-19</u>. https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/ 3 CDC Covid-19 Website . https://www.cdc.gov/coronavirus/2019-ncov/index.html



